Last reviewed · How we verify
NCT06847750
Elastography Ultrasound in Localized Scleroderma (Morphea) Study
trial testing Elastography Ultrasound in Scleroderma in 20 participants. Enrolling by invitation.
30 March 2026
Quick facts
| Lead sponsor | The Hospital for Sick Children |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 10 March 2023 |
| Primary completion | 30 March 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Elastography Ultrasound
- The Localized Scleroderma Quality of Life Instrument (LoSQI )
Conditions studied
- Scleroderma — all drugs for Scleroderma →
Sponsor
The Hospital for Sick Children
Who can join
Under 18, any sex, with Scleroderma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Localized scleroderma (LS) is a skin disease that can cause complications such as disfigurement and limitation of mobility. Treatment for LS should be initiated early in the disease, as late-stage scleroderma does not respond well to treatment. Objective tools for diagnosis and follow-up of treatment for LS are not available clinically and are urgently needed. A new non-invasive ultrasound technique called "elastography" measures stiffness of tissues and holds potential for providing objective measures for follow-up of treatment of LS in children and adolescents. The team plans to conduct a multicenter study in North America to determine whether elastography ultrasound can show changes in skin stiffness for a period of 9 to 12 months after initiation of treatment for LS. This novel technology may add information to the existing imperfect clinical tools, thus improving the way therapy is offered to patients with LS.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06847750
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Scleroderma
Currently open trials in the same condition.
- NCT07292961 — Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed Wi · NA · recruiting
- NCT06801119 — Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs） · Phase 1 · recruiting
- NCT06554132 — Respiratory Muscle Strength and Aerobic Capacity in Scleroderma · recruiting
- NCT03800017 — Skeletal Muscle Function in Interstitial Lung Disease · NA · recruiting
- NCT06598982 — Investigation of Respiratory Muscle Sarcopenia in Patients With Systemic Sclerosis · recruiting
Other The Hospital for Sick Children trials
Trials by the same sponsor.
- NCT07454681 — MRI Assessment of Lung Airways in Cystic Fibrosis: Evaluate MRI's Ability to Detect Changes in Airway Structure . · not yet recruiting
- NCT07452575 — 3D Ultrasound in Hemophilic Ankles · NA · not yet recruiting
- NCT07508826 — AI-assisted Endotracheal Intubation · NA · not yet recruiting
- NCT07345819 — Dexamethasone vs. Placebo in Children and Youth Hospitalized for Orbital Cellulitis · NA · not yet recruiting
- NCT07497178 — MRgFUS for Childhood Epilepsy · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06847750 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Hospital for Sick Children
- Last refreshed: 26 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06847750.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing